Prelude Therapeutics (PRLD) Cash from Operations Growth (1y) (2020 - 2026)

Prelude Therapeutics (PRLD) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 7.14%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 356.73%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.23%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Prelude Therapeutics 324.30 Mn 179.71 Mn - 36.65%

Historic Data

Download Data
DateValue
Mar 31, 2026 36.65%
Dec 31, 2025 211.45%
Sep 30, 2025 29.97%
Jun 30, 2025 -13.09%
Mar 31, 2025 -7.68%
Dec 31, 2024 12.02%
Sep 30, 2024 -6.28%
Jun 30, 2024 16.67%
Mar 31, 2024 -5.50%
Dec 31, 2023 -2.84%
Sep 30, 2023 -25.66%
Jun 30, 2023 -49.82%
Mar 31, 2023 -37.63%
Dec 31, 2022 10.80%
Sep 30, 2022 6.13%
Jun 30, 2022 7.25%
Mar 31, 2022 -35.63%
Dec 31, 2021 -73.11%
Sep 30, 2021 -74.09%
Jun 30, 2021 -123.68%